RBC Capital raises Revolution Medicines price target to $259
RBC Capital raised its price target on Revolution Medicines to $259 from $251, keeping its rating at Outperform, according to a Benzinga report.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.